Literature DB >> 2850408

[Biological significance of estrogen receptor status in axillary lymph node metastases of invasive ductal breast cancers].

H A Horst1, H P Horny, H J Gent, C Sellschopp, J Hedderich.   

Abstract

One hundred and fourty-nine axillary lymph node metastases of 35 female patients with invasive breast carcinomas were investigated immunohistochemically for their estrogen receptor (ER)-status. In addition, proliferative activity of the metastatic deposits was determined with the monoclonal antibody Ki-67. Twenty-four primary tumours were ER+ and 11 ER-. Lymph node metastases were ER+ in 21 of the 24 cases where the primary tumour was ER+. In 10 of the 11 cases with ER- primary tumours, the metastases were also ER-. In any given case, the lymph node metastases proved to be either all ER+ or all ER-. Negative ER-status was found to be related to higher numbers of axillary node metastases and higher maximum proliferative activity of the metastatic tumours. Follow-up at 2 years after diagnosis revealed a significantly lower incidence of distant metastases in patients with ER+ primary tumours.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2850408     DOI: 10.1007/bf01727662

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  31 in total

1.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

Review 2.  The usefulness of steroid hormone receptors in the management of primary and advanced breast cancer.

Authors:  W L McGuire
Journal:  Eur J Cancer       Date:  1980       Impact factor: 9.162

3.  The prognostic value of estrogen receptor determinations in patients with primary breast cancer: an update.

Authors:  P Furmanski; D E Saunders; S C Brooks; M A Rich
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

4.  Estrogen receptors and long-term prognosis in breast cancer.

Authors:  S Aamdal; O Børmer; O Jørgensen; H Høst; G Eliassen; O Kaalhus; A Pihl
Journal:  Cancer       Date:  1984-06-01       Impact factor: 6.860

5.  Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast.

Authors:  J F McGurrin; M I Doria; P J Dawson; T Karrison; H O Stein; W A Franklin
Journal:  Cancer       Date:  1987-05-15       Impact factor: 6.860

6.  Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading.

Authors:  F F Parl; B P Schmidt; W D Dupont; R K Wagner
Journal:  Cancer       Date:  1984-11-15       Impact factor: 6.860

7.  Estrogen receptors and the pattern of relapse in breast cancer.

Authors:  R Qazi; J L Chuang; W Drobyski
Journal:  Arch Intern Med       Date:  1984-12

8.  Variation in receptor status between primary and metastatic breast cancer.

Authors:  I M Holdaway; J V Bowditch
Journal:  Cancer       Date:  1983-08-01       Impact factor: 6.860

9.  Distribution of estrogen and progesterone receptors on primary tumor and lymph nodes in individual patients with breast cancer.

Authors:  K Klinga; M Kaufmann; B Runnebaum; F Kubli
Journal:  Oncology       Date:  1982       Impact factor: 2.935

10.  Inter-site variation of oestrogen receptors in human breast cancers.

Authors:  W D Tilley; D D Keightley; E L Cant
Journal:  Br J Cancer       Date:  1978-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.